Company news
PolyPid Ltd. news in 2022
PolyPid Ltd.'s news releases, calls and decks from 2022, newest first.
PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
December 11, 2022
PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification
December 8, 2022
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association
November 28, 2022
PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 8, 2022
PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022
October 25, 2022
PolyPid Announces Cost Reduction Plan
October 19, 2022
PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery
September 27, 2022
PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery
September 18, 2022
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society for Coloproctology Scientific Conference
September 11, 2022
PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery
September 1, 2022
PolyPid Announces Presentation at the 2022 Military Health System Research Symposium
August 29, 2022
PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 9, 2022
PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀₀ in Europe
August 2, 2022
PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022
July 26, 2022
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting
July 24, 2022
PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO
July 4, 2022
PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022
June 5, 2022
PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects
May 31, 2022
PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery
May 30, 2022
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis
May 22, 2022
PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 10, 2022
PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting
April 11, 2022
PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility
April 5, 2022
PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery
March 1, 2022
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
February 8, 2022
PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board
January 3, 2022
PolyPid Announces Planned CEO Transition
January 2, 2022
Calls in 2022
Decks in 2022
- Corporate Update (June 2022)
Corporate update · 42 slides · June 2022